These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The expression of nm23-H1 genes with clinical prognosis in endometrial carcinoma].
    Author: Guo C, Wei L, Fu Q.
    Journal: Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):423-5. PubMed ID: 11360656.
    Abstract:
    OBJECTIVE: To study the expression of nm23-H1 gene in endometrial carcinoma and its relationships between the clinicopathological parameter and prognosis of endometrial carcinoma. METHODS: The endometrial specimens of 60 cases with endometrial carcinoma were studied retrospectively by immunohistochemical stainings. RESULTS: The positive expression rate of nm23-H1 gene in endometrial carcinoma was 55.0% (33/60). The positive rate of nm23-H1 in early endometrial carcinoma was significantly higher than that in advanced cases (65.9% and 25.0%, respectively, P < 0.05). Positive rates in the well and moderately differentiated endometrial carcinoma were also higher than those of poorly differentiated (66.7%, 63.6%, 29.4%, P < 0.05). 20.0% of the cases with and 64.9% of the cases without lymph node metastasis showed positive for nm23-H1 (P < 0.05). The expression of nm23-H1 was not correlated with histological type, myometrial invasion, estrogen receptor and progesterone receptor. The survival rate of patients with nm23-H1 expression was significantly higher than that of patients without nm23-H1 expression. The 5-year survival rate was 90.5% and 55.3% respectively (P < 0.05). CONCLUSION: nm23-H1 gene may play a role in the inhibitory effect on the development and the lymph node metastasis of endometrial carcinoma, and may be related to be prognosis of endometrial carcinoma.
    [Abstract] [Full Text] [Related] [New Search]